Hengrui Pharmaceutical (600276): 19Q3 performance exceeded market expectations and growth was significantly faster than the previous quarter

Hengrui Pharmaceutical (600276): 19Q3 performance exceeded market expectations and growth was significantly faster than the previous quarter

Event: The company’s third quarter of 19 reported that net profit attributable to mothers increased year by year28.

26%.

Hengrui Pharmaceutical released the third quarter report of 19, and achieved operating income of 169.

45 ppm, an increase of 36 in ten years.

01%; net profit attributable to mother 37.

35 ppm, an increase of 28 in ten years.

26%; net profit of non-return to mother is 35.

360,000 yuan, an increase of 27 in ten years.

25%.

The company achieved operating income of 69 in the single quarter of 19Q3.

190,000 yuan, an increase of 47 in ten years.

27%; net profit attributable to mother 13.

22 ppm, an increase of 31 in ten years.

96%; deducted non-attributed net profit 12.

470,000 yuan, an increase of 31 in ten years.

15%.

The company’s performance exceeded market expectations.

The trend of accelerating performance growth is clear, and the R & D growth continues to grow rapidly.

The company’s 19Q3 single quarter revenue increased by as much as 47.

27%, far exceeding market expectations. It is expected that this is mainly related to the accelerated sales of angiography and tumor lines. The company’s performance growth has shown a quarter-on-quarter acceleration trend again and has been confirmed again.

According to the company’s announcement, the current contrast agent channel is still seriously out of stock and is expected to maintain a growth rate of about 40% in the first three quarters; the tumor line is expected to increase to 40% driven by the amount of carelizumab and albumin paclitaxelabout.

In the first three quarters of 19, the company’s R & D investment reached 28.

99 ppm, a 66-year increase of 66.

97%, R & D expense ratio increased to 17.

11% (+3.

17pct), in which the R & D expense ratio reached 19 in the single quarter of 19Q3.

46% (+4.

68pct); The continuous high R & D promotion has further strengthened the company’s innovative drug leader.

In addition to the rapid growth of the R & D expense ratio, the company’s overall expense ratio was well controlled during the first three quarters of 19 (61.

83%, +3.

40pct), of which selling expenses cost 36.

37% (-0.

89 points), management costs 8.

98% (+0.

95pct), financial expenses budget -0.

63% (+0.

17pct).

The company’s accounts receivable reached 54.19 trillion, an earlier increase of 43.

63%; net cash flow from operating activities in the first three quarters26.

08 million yuan, an increase of 27 in ten years.

19%, basically the same as the rate of profit growth.

Karelizumab’s indications continued to develop, and the launch of innovative drugs helped boost performance.

The company is a leader in conventional innovation and R & D. The R & D expansion continues to grow at a high rate. Driven by years of high R & D promotion, the company has gradually entered the innovation harvest period.

At the front end, the company’s heavy-duty innovative or high-end imitation products such as irexexib, thiopefilgrastim, pirlotinib, albumin paclitaxel, and carelizumab have been approved for listing.

It is particularly noteworthy that the company’s Karelizumab has achieved excellent clinical progress in lung cancer, liver cancer, gastric cancer, esophageal cancer and other large cancer indications, and its research and development progress is leading internally.

According to the company announcement and CDE data disclosure, the company has successively delivered second-line treatment for esophageal squamous cell carcinoma, second-line treatment for liver cancer monotherapy, and NSCLC combined with first-line treatment for chemotherapy.

With the continuous development of Karelizumab for large cancer indications, and overlapping the company’s strong channel access and commercialization capabilities, the sales of Karelizumab are expected to reach 10 billion US dollars.

The company’s pirlotinib was approved for conditional marketing based on phase II clinical data in August 18 and was approved for use in combination with capecitabine for second-line treatment of HER2-positive patients.

At present, the company announced that the main endpoint of the Phase III clinical study of pirlotinib combined with capecitabine in the treatment of advanced diabetes has reached the standard of mid-term analysis of superiority of the protocol, and the safety is acceptable. Compared with lapatinib combined with capecitabine,Can 四川耍耍网 significantly prolong the patient’s PFS.

In terms of other research varieties, the company’s PD-L1 monoclonal antibody SHR-1316 combined with first-line chemotherapy for extensive-stage small cell lung cancer is already in the phase III clinical trial, and first-line therapy with chemotherapy for esophageal squamous cell carcinoma is also in the phase II clinical trial. The future progress will be the first to win domestically.Batch listing.
In addition, the company’s innovative drugs such as bevacizumab, type II diabetes treatment drug SGLT-2 inhibitor SHR3824, prostate cancer treatment drug androgen receptor antagonist SHR3680, hormone receptor antagonist treatment drug CDK4 / 6 inhibitor SHR6390 orBiosimilar drugs have also entered phase III clinical trials, and are expected to continue to contribute to the company’s performance 杭州夜网论坛 flexibility in the future.

Investment recommendation: Overweight-A investment rating, 6-month target price of 90.

60 dollars.

According to the company’s first three quarters of performance, we slightly raised the company’s profit forecast. It is expected that the company’s revenue growth from 2019 to 2021 will be 34.

6%, 30.

8%, 27.

9%, net profit growth rate was 28.

8%, 27.

8%, 25.

5%, outstanding growth; given Overweight-A investment rating, 6-month target price is 90.

60 yuan, equivalent to a dynamic price-earnings ratio of 60 in 2020.

Risk warning: product price reduction risk, core product marketing is less than expected, new drug development is less than expected, etc.

Juewei Food (603517) 2019 Quarterly Review: Opening Stores Still Accelerating and Stabilizing

Juewei Food (603517) 2019 Quarterly Review: Opening Stores Still Accelerating and Stabilizing
Matters: The company released the first quarter report of 2019 and achieved operating 西安耍耍网 income11.500 million, an increase of 19.6%, net profit attributable to mother 1.800 million, an increase of 20.4%, deducted non-net profit1.800 million, an increase of 21.2%, achieving a budget benefit of 0.44 yuan. Q1 results were in line with expectations.Q1 company revenue increased by 19.6%, slightly higher than market expectations.The gross profit margin was 33.3%, down by 1.1pct, period cost cost 13.0%, down with 0.3pct, net profit increased by 20.4%, in line with market expectations. Q1 speeded up the opening of the store, and “Jiaojiao” made a new income.Q1 income increased by 19.6%, slightly exceeding market expectations.The company achieved high growth in the first quarter, with a low base factor, but more from: 1) The speed of opening stores has accelerated significantly. We expect a net increase of about 250 stores in the first quarter, which will create a new high since the past five quarters and store stockThe total number is 10100+; 2) Benefiting from store upgrades, the same-store revenue growth rate is stable at 3% -5%; 3) New categories of “pepper flavor” are popular with consumers, and 20+ stores are expected to open in Q1.In the initial period, about 200 stores were opened, creating a new growth point in performance.In terms of products, fresh poultry revenue was 9.0 ppm, accounting for 80%, contributes the main income, followed by vegetables1.100 million, accounting for 10%. In terms of regions, Central China, Eastern China, and Southern China accounted for a relatively high income, which were 27.1%, 17.0%, 25.0%, there is still room for development in the northwest. Expense rates have steadily declined, and net interest rates have hit record highs.The net profit attributable to the mother increased by 20 in Q1.4%, maintaining stable growth; net interest rate is 15.7%, a new high since 2014.1) The gross profit margin dropped slightly.Q1 gross profit margin was 33.3%, down by 1 every year.1pct, mainly due to the rise of duck intestines, duck tongues and other deputy prices in the first three quarters of 18 years, which declined in the fourth quarter. A small portion of 1Q19 used raw materials purchased in 3Q18. At the same time, prices of auxiliary materials such as pepper increased, and some hedged 4Q18 The fall of duck deputy prices led to a decline in gross profit margin in 1Q19.In 19 years, the price of duck deputy purchases has been relatively reduced, and the pressure on raw material costs has eased. 2) The cost rate has declined steadily.Expenses during Q113.0%, down with 0.3pct, of which selling expenses cost 7.3%, basically the same as the same period last year; considering internal R & D expenses, administrative expenses 56%, down by 0.4pct. Maintaining a steady store opening, continued improvement in profitability can be expected.According to the company’s strategy, Juwei Duck Neck stores maintained a high net increase of 800-1200 stores, accelerated the development of high-potential energy stores, and promoted the online and offline integration and development, and the revenue flexibility will continue to increase.In 19 years, the company began to launch a new brand “Jiaojiayouwei”. The store opening has been effective from the region to the country, and the speed of opening stores will be accelerated in the future.In addition, the company has participated in multiple food chain and catering projects. When the project matures, it is expected to form a brand fission and form a new growth point.In the long run, the company is expected to maintain a stable performance growth rate. Earnings forecasts and investment advice.As a leader in leisure halogen products, the channel, production capacity and scale advantages are obvious. The expansion of stores and endogenous growth will increase the company’s performance, and new categories are steadily advancing, which is expected to become a new growth point.We expect the company’s 19-21 operating income to be 50.23/57.26/64.71 ppm with a growth rate of 15.0% / 14.0% / 13.0%; net profit is 7.97/9.62/11.37 trillion, with a growth rate of 24.4% / 20.8% / 18.1%; EPS is 1.94/2.35/2.77 yuan, corresponding PE is 24/20 / 17X, maintaining the “recommended” level. Risk reminders: pressure on duck deputy prices, store opening speed is slower than expected, food safety issues.

Limin Shares (002734): Grasshopper Spodoptera exacerbated by damage will significantly benefit companies

Limin Shares (002734): Grasshopper Spodoptera exacerbated by damage will significantly benefit companies

Event Overview The Ministry of Agriculture and Rural Affairs issued the “Plan for Preventing and Controlling Spodoptera litura in 2020” (hereinafter referred to as “Plan”) on February 20, stating that the situation of Spodoptera frugiperda in 2020 will become more serious and the task of prevention and control will be more difficult.

  Analysis and judgment: Spodoptera frugiperda is more harmful to national agriculture than obesity in Africa.

  According to the “Plan”, after the grasshopper Spodoptera frugalis invaded the Yunnan area for the first time in January 2019, damage occurred in the corn growing areas of six provinces in southwest China from November to January 2020. Grasshopper Spodoptera frugalis was found in 25 provinces across the countryThe area of insect pests has exceeded 16 million mu. The occurrence of local insect pests has been advanced this year, and overseas insect sources have continued to move in. It is predicted that the damage of Spodoptera frugiperda will increase in 2020. It is expected to threaten more than 50% of the corn planting area and affect about 1 billion muSugarcane, sorghum, and winter wheat in areas south of Huanghuai are also at risk from southwestern and southern China.

From the perspective of the harm situation and occurrence area, the potential harm of Spodoptera frugiperda to annual farming this year is far greater than that of farmland disasters in Africa.Within the target of “%”, selecting effective pesticides will be the top priority for ensuring the safety of food production in 深圳桑拿网 2020.

Avicinium is the main drug for controlling Spodoptera frugiperda, and the company will benefit significantly.

  The “Preliminary” list of emergency prevention medications for Spodoptera frugiperda includes 8 single-dose preparations such as methylamino abamectin benzoate, 14 compound preparations such as metavinium salt and indoxacarb, of which 14Eight of the formulations require metformin or avermectin, compared with 6 of the 8 formulations in the National Grasshopper Spodoptera control program issued by the Ministry of Agriculture on June 21, 2019.Compounded with methanoate, it shows that methanoate has outstanding effects on Spodoptera frugiperda in 2019, and has been approved by the policy. It will become the main species for prevention and control in 2020.

Weimin Biochemical, which is controlled by Limin, is a domestic leader in avermectin and carbamate, with carbamate accounting for 15% of domestic cities, and the largest market among listed companies. Weiyuan Jinlanrui (15% carbamate)· Indoxacarb) won the best-selling brand of pesticides in China’s plant protection market in 2018.

With chemical pesticides as the main preventive measures, the compound of metformin is the main drug recommended in the “Plan”, and the company will benefit significantly.

The supply and demand pattern of Awei salt is improving, and prices have recently started to rise.

  According to Zhuochuang Information, Chutianyuan Chemicals and Jinghong Technology are located in Hubei Province. The recent production has been affected by the epidemic situation, and the market supply has declined. Since February, 70% of the original medicine prices of methanoate have been changed from 1.01 millionYuan / ton rose to 106 million / ton, and the future supply and demand pattern is expected to drive the price increase.

The company-controlled Weiyuan currently has a 300-tonne salt production capacity. According to the company’s announcement on July 18 last year, it is allowed to continue to expand its production capacity and will make full use of the situation.

  The investment proposal estimates that the company’s operating income for 2019-2021 will be 29.

61/44.

70/53.

2.5 billion, net profit to mother is 3.

45/4.

74/5.

92 trillion, EPS is 1.

20/1.

66/2.

07 yuan, the current corresponding PE is 12/9/7 times.

The company’s acquisition of Weiyuan has shifted to the top ten of the domestic pesticide industry, and its comprehensive competitiveness has been significantly enhanced. This year, the product A and M salts will benefit from the upgrade and control of Spodoptera frugiperda.

Covered for the first time, giving “overweight” rating.

  Risks indicate the risk of falling product prices; the risk of delayed construction of new projects.

Orchid Science and Technology (600123): Volume increase, price decline, performance

Orchid Science and Technology (600123): Volume increase, price decline, performance

This report reads: The decline in sales prices of main products has led to poor overall performance of the company, and the expected increase in performance due to bankruptcy and liquidation of subsidiaries cannot be achieved.

Investment Highlights: Revise down earnings forecasts and maintain a “cautious increase” rating.

Revenue in the first three quarters of 2019 was 四川耍耍网 61.

6.1 billion yuan, net profit attributable to mother 7.

400,000 yuan, achieving a budget income of 0.

65 yuan, down 25 before.

15%, lower than expected results.

We lower the 2019-20EPS to 0.

81/0.

83 yuan (previous forecast was 0.

97/1.

04 yuan), plus EPS0 forecast for 2021.

84 yuan, maintaining a target price of 6.

96 yuan, corresponding to 2019 PE8.

6 times, maintain the “cautious increase” rating.

Product sales have risen, prices have fallen, and overall operating performance has declined.

In the first three quarters, the company sold 611 products such as coal, urea, dimethyl ether, and lactam.

37/67.

96/21.

86/8.

93 Initially, it is increased by 13 each year.

9% / 7.

9% / 5.

3% /-1.

5%, the calculated unit of coal / urea / dimethyl ether / lactam replaced 570/1714/2835/11215 深圳桑拿网 yuan, a decrease of 11.

1% / 1.

9% / 20.

5% / 19.

6%.

The sharp drop in prices dragged down performance, and Orchid Science and Technology achieved operating profit in the first three quarters9.

$ 1.6 billion, an average of 22 per year.

2%.

Subsidiary bankruptcy and liquidation will increase company performance.

The report summarizes that Chongqing Lanhua Solar, a subsidiary of the company, has entered bankruptcy liquidation procedures and will no longer consolidate the scope of consolidated statements. It will write back the offsetting impairment loss of 264.9 million yuan. The previous year’s excess income will be transferred back to confirm the investment income of 190.48 million yuan, a total amount of 4.

5.9 billion, increasing company performance.

Interest-bearing debt has been compressed, financial costs have fallen, and debt ratios have remained low.

Total scale of short-term borrowings in the first three quarters / non-current debt due within one year / long-term borrowings.

29 ppm, a decrease of 2 per year.2%, incurring financial expenses 2.

4.5 billion (down 18 a year.

6%).

The gearing ratio increased by 1 compared with the beginning of the period.

03PCT, reaching 55.

45%, still relatively low in three years.

risk warning.

Falling prices of coal and chemical products; the impact of environmental protection and limited production; macroeconomic risks.

Jin Shiyuan (603369): Benefiting from consumption upgrades and channel expansion The sub-high-end country edge maintains rapid growth

Jin Shiyuan (603369): Benefiting from consumption upgrades and channel expansion The sub-high-end country edge maintains rapid growth

Benefiting from the consumption upgrade in the province, the next high-end national border income maintained rapid growth. The company announced 19H1 revenue 30.

570,000 yuan, an increase of 29.

4%, second quarter revenue 11.

20,000 yuan, an increase of 26.

55%.

19H1 Special A + Class 北京桑拿洗浴保健 Income 16.

740,000 yuan, an increase of 44.

33%, accounting for 54% of alcohol revenue.

98% in the second quarter of 19Q2, an increase of 43.

51%; 19H1 special A income 9.

730,000 yuan, an increase of 20.

58%, increased by 14 in the second quarter of 19Q2.

73%.

In terms of regions, Nanjing’s dominant market, the company’s revenue, increased by 48 in 19H1.

88% in the second quarter of 19Q2, an increase of 41.

38%; Huaian revenue in 19H1 increased by 16.

75% in the second quarter of 19Q2, an increase of 28.

88%.

19H1 income outside the province increased by 51.

42% in the second quarter of 19Q2, an increase of 28.

03%, the growth rate has improved. According to Weijiu, the company has been attracting investment outside the province for 18 years, so the base in 18Q1 is low.

  19H1 returns to 重庆耍耍网 mother’s net profit 10.

720,000 yuan, an increase of 25.

23% in the second quarter of 19Q2, an increase of 24.

1%.

The gross profit margin for 19H1 was relatively increased by 0.

03 PCT to 71.

96%.

19H1 maximizes the sales expense ratio by 0.

37 PCT to 12.

85%; the management expense ratio decreases by 0 every year due to the scale effect.

38 PCT to 2.

58%.

  In 19H1, the company’s business tax and additional revenue increased by 1.

13 PCT to 13.

57%, mainly due to the adjustment of the consumption tax policy in May 2018.

  Accelerate channel expansion and cultivate high-end new products, and promote rapid growth in revenue. According to the company’s annual report, the company’s 19-year goal is to increase revenue by about 30% and net profit by about 25%.

Jiangsu’s sub-high-end market is growing rapidly. We expect CAGR to be about 25% in the next three years. The Guoyuan series is positioned as a sub-high-end, with high cost-effective products and strong channel thrust. It is expected that it will maintain relatively rapid growth in the future.However, considering that the company is still in the growth stage, the sales expense ratio is expected to increase.

  Earnings forecast We expect the company’s revenues to be 48 in 19-21.

85/61.

16/73.

470,000 yuan, an increase of 30 in ten years.

57% / 25.

20% / 20.

13%, net profit attributable to mothers is 14 respectively.

40/18.

45/22.

80 ppm, an increase of 25 in ten years.

13% / 28.

14% / 23.

58%, EPS is 1.

15/1.

47/1.

82 yuan per share, the PE corresponding to the latest closing price is 24/18/15 times, the company’s 19-21 year performance CAGR is expected to be 26%, and it will give about 26 times PE in 19 years, PEG is about 1, and a reasonable value of 30 yuanStocks, maintain BUY rating.

  Risk reminder: intensified market competition in the province, structural upgrade exceeding expectations, food safety issues

Tailor-made fitness methods for travelers

Tailor-made fitness methods for “travelers”

When you are traveling for business or traveling, it may disrupt your regular fitness training.
Try not to let this happen, use the equipment around you to exercise, and minimize losses.
20 minutes can fully mobilize the muscles of the whole body.
All you need is a chair, a cushion, and your own body.
  Exercise in the order of A, B, C, D, and rest for one minute between each group.
After doing this round, just repeat it again.
  A.
Squat with legs and do 15-20 times; B.
Do push-ups on the chair with your hands, as many times as possible; C.
Jump from bed to mat on the ground and do 15-20 times; D.
Use your chair to do a front lift, 12 to 15 times.

Pineapple diet side: pineapple grass root honey soup cough and asthma

Pineapple diet side: pineapple grass root honey soup cough and asthma

The weather is warming, and the fruit stands on the streets and alleys exude the aroma of fruits. Among them, the rich pineapple aroma is most attractive!

Pineapple has a strong fruit aroma and has always been a favorite fruit.

Pineapple is always delicious and it has some medicinal value.

  Li Shizhen recorded in “Compendium of Materia Medica” that “Pineapple can nourish the spleen and stomach, solidify vitality, suppress excessive hypertrophy, support stagnation, spirit-like, nourishing qi, relieve phlegm, relieve toxic effects, quench thirst after drinking, sharp leader, happyYizhi.

“Traditional Chinese medicine believes that pineapple is sweet, slightly acidic, and flat.

It has the functions of clearing heat and quenching thirst, eliminating food and stopping diarrhea, reducing swelling and dampness, and can be used for indigestion, diarrhea, hypotension, edema, adverse urination, and diabetes.

Modern research has found that pineapple contains protein, sugars, starches, vitamins B1, B2, C, carotene, niacin, minerals such as calcium, phosphorus, iron, and various organic acids, pineapple enzymes and so on.

  Pineapple contains biological compounds and bromelain, which can both eliminate thrombus and inhibit thrombus formation early.

The thrombus is the leading cause of myocardial infarction and cerebral thrombosis.

Therefore, pineapple is an ideal fruit for patients with hypertension and has a relief effect on heart disease caused by thrombosis of coronary and cerebral arteries.

  Pineapple can be eaten after meals, can be appetizing and smooth, degrease and help digestion.

Mexicans often use pineapple as a medicinal liquor for appetizing and digestive purposes.

  Pineapple is tempting, but it can’t be eaten by people with eczema and scabies.

Pineapple contains a biological protein and bromelain.

Biological additives can irritate the oral mucosa and make people feel itchy after eating. Some people are allergic to bromelain. Therefore, when eating fresh pineapple, it is best to peel and cut into pieces and soak in salt water to destroy the pineapple activity.Avoid allergies.

  Few pineapple diet recipes: 250 grams of fresh pineapple juice, pineapple meat, washed, twisted juice, add 1 cup of cold water, appropriate amount of salt, mix well and take in two portions.

  It is suitable for patients with asthma and thirst and indigestion.

  Pineapple fried chicken slices Wash 250 grams of pineapple meat and 100 grams of chicken breasts, and cut into thin slices.

Put chicken breast slices and salt first, stir fry until half cooked, then fry the pineapple with the right amount of water, cover for a while, simmer until cooked, add MSG, pepper, and stir well.

Take it alone or with your meal.

  Suitable for patients with low blood pressure and dizziness, weak hands and feet.

  Pineapple grass root honey soup 100 grams of pineapple meat, soak slightly in brine, wash and slice.

50g of grass root, washed and cut off.

Add 600 ml of water, put both in water, fry to 300 ml, remove residue, add honey, and continue to heat to boil.

  Suitable for patients with bronchitis.

What are the nutritional values of cabbage

What are the nutritional values of cabbage

Cabbage, also known as cabbage, is a vegetable with a lot of nutritional value. If you eat properly, it is very good for our health. At the same time, it has a high medicinal value, so it is so popular.

So, the nutritional value of cabbage is so much, which one do you know?

  First, cabbage is rich in vitamin C, vitamin E, β-carotene and other elements needed by the human body. The vitamin content of a cabbage is much higher than that of a tomato by 3 times, soNormally moderate consumption is beneficial to the human body’s antioxidant effect, anti-aging, and youth protection.

  Second, the packaging material is rich in propyl isothiocyanate derivatives, which can effectively kill abnormal cells that cause human leukemia.

If you eat fresh cabbage, it can be effective and can also help treat human wound inflammation and disinfection.

 If you eat fresh cabbage, it can be effective and can also help treat human wound inflammation and disinfection.

  Third, cabbage contains a large amount of sulforaphane. This element helps to produce enzymes that are beneficial to the body, thereby forming a protective film that can effectively resist the erosion of carcinogens.

Eating cabbage can also help digestion and strengthen the function of the spleen and stomach.

  Although cabbage tastes crispy and tastes sweet, it is a relatively cold food. If a person with a weak constitution eats it often, it will easily cause physical discomfort.

Psychology-the psychology of husband and wife affair

Psychology: the psychology of husband and wife affair

Loneliness Due to work or separation between the two places, some husbands are often away from their wives.

If such a husband lacks a sense of family responsibility, does not care about his wife, and does not often express his feelings of love in various ways, over time, it will inevitably make the relationship between husband and wife tend to be indifferent, the wife will have a lonely psychology, and feel no spiritual support.

At this time, if a suitable opposite sex is encountered, the wife will lose the ability to resist temptation, leading to extramarital affairs.

  Resentment of psychological sexual life is a very important content in the life of husband and wife.

If a partner, because of sexual dysfunction, or is busy pursuing a career, neglects to give each other warmth, or the husband is greedy for wine, and cannot meet his wife’s normal physiological needs, over time, it will cause his wife to have resentment, which is extremely likely. “Red apricots come out of the wall. ”

  Lost psychology is more common in the lack of understanding before marriage, “love at first sight”, hastily married; or just “love to cook mature rice” and “involuntary.”

After living together for a long time after marriage, they gradually found that each other had many bad problems or some physical defects.

In this case, it is easy to produce a sense of psychological loss and germination.

  Some women meet the standard for some purpose, committed to men who do not like it.

Due to their lack of emotional basis with their husbands, once their goals are achieved, they will feel that the husband is old or ugly, either ending with divorce or “holding another lute”.

  Some revenge husbands are unfaithful to their wives and cheat on the outside. Once things are revealed, they often lead to unpleasant endings.

If the consideration of being a wife is not appropriate, you may have revenge when you are angry: Since you can slap flowers outside, then why can’t I look for sustenance?

  Some wives have higher education or higher education than their husbands, or some husbands, if they are not willing to be aggressive, they can easily make their wives “hate iron and steel” and feel that their husbands are not worthy of themselves.

Therefore, wives who are better than their husbands in all aspects have a broken chance of extramarital affairs, because there are likely to be men around them who are better than their husbands.

  In view of the above, in order to improve the quality of marriage, both husband and wife should understand the psychological trajectories of extramarital affairs, strengthen communication, start with themselves, and adjust the relationship between husband and wife in a timely manner so that they can continue to be sublimated.

In this way, the stability of the family and the happiness of marriage can be guaranteed.

Seven Yoga Practices

Seven Yoga Practices

It is a well-recognized fact that the waist is easy to grow meat. In addition to controlling the diet, proper exercise is essential.

Today I will teach you a few thin waist yoga exercises to achieve your dream of a bee waist woman.

  1. Plow type ① Lie on your back with your feet close together, legs straight, slowly lift your feet off the ground, and reach the top of your head, with your toes touching the ground, your upper arms supporting the ground, and your hands supporting your head.

  ② Slowly loosen your hands, keep your hips up, and insert them straight on the floor, with your palms facing the ground and straight forward.

  2. The dog-down variant puts your feet together, your legs straight, your toes point to the ground, your heels are off the ground, your body is bent down, and you stand on the floor with your hands around your head, your elbows on the ground, and your toes are raised forwardPush forward.

  3. Stand in a wheeled position, with your feet separated from each other, and lean forward and backward until you straighten forward and your hands are on the ground.

This action is difficult to break, and beginners are advised not to try it.

  4, L-shaped sitting position, feet close together, legs straight into the floor, feet tight, toes pointed and straight forward, hands fists and placed in front of the chest, straight and straight, eyes look forward.

  5, supine supine, lying next to the ground, feet apart, the toes point forward, straight into the floor, away from the body, take a deep breath.

  6, kneeling posture, knees forward, feet close to each other, hips sitting on the heels, hands and fingers holding each other, the body is bent, the forearms are placed on the floor, support the body, the tibia is lowered, the abdomen is close to the thigh surface, firmly straight.

  7, sitting twisted sitting position, right leg on the floor and bend, heel close to step in front, left foot across the right leg to insert forward, straight forward, twist forward to tilt, right arm close to the outside of the left calf, And holding the left foot to reset, the left arm is stretched to the left rear, and the head is twisted back.